IMC-A12
Sponsors
Eli Lilly and Company, University of Washington, National Cancer Institute (NCI), M.D. Anderson Cancer Center
Conditions
Advanced Solid TumorsBrain Stem NeoplasmsColorectal CancerGliomaHead and Neck Squamous Cell CarcinomaPeritoneal MesotheliomaPinealomaPleural Mesothelioma
Phase 1
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
CompletedNCT00785538
Start: 2005-10-31End: 2011-01-31Updated: 2019-01-08
A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
CompletedNCT00785941
Start: 2006-04-30End: 2007-11-30Updated: 2011-10-13
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
WithdrawnNCT01182883
Start: 2010-07-28End: 2012-04-04Updated: 2017-07-02
Phase 2
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
CompletedNCT00503685
Start: 2007-06-30End: 2009-03-31Updated: 2018-06-06
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
CompletedNCT00683475
Start: 2008-08-31End: 2011-09-30Updated: 2014-10-16
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
CompletedNCT00769795
Start: 2008-10-31End: 2011-11-30Updated: 2017-03-29
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
TerminatedNCT00778817
Start: 2008-12-31End: 2014-03-31Updated: 2014-04-29
Preoperative Treatment With Cetuximab and/or IMC-A12
CompletedNCT00957853
Start: 2011-10-17End: 2018-08-15Updated: 2020-03-19
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
CompletedNCT01160458
Start: 2010-06-02End: 2017-02-24Updated: 2018-04-10